J
Jacoline E C Bromberg
Researcher at Erasmus University Rotterdam
Publications - 103
Citations - 10921
Jacoline E C Bromberg is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Primary central nervous system lymphoma & Rituximab. The author has an hindex of 31, co-authored 95 publications receiving 9357 citations. Previous affiliations of Jacoline E C Bromberg include Erasmus University Medical Center & Utrecht University.
Papers
More filters
Journal ArticleDOI
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi,Annie-Claire Diserens,Thierry Gorlia,Marie-France Hamou,Nicolas de Tribolet,Nicolas de Tribolet,Michael Weller,Johan M. Kros,Johannes A. Hainfellner,Warren P. Mason,Luigi Mariani,Jacoline E C Bromberg,Peter Hau,René O. Mirimanoff,J. Gregory Cairncross,Robert C. Janzer,Roger Stupp +16 more
TL;DR: Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylation of theMGMT promoter did notHave such a benefit and were assigned to only radiotherapy.
Journal ArticleDOI
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Walter Taal,HM Oosterkamp,Annemiek M E Walenkamp,Hendrikus J. Dubbink,Laurens V. Beerepoot,Monique Hanse,Jan Buter,Aafke H. Honkoop,Dolf Boerman,Filip de Vos,Winand N.M. Dinjens,Roelien H. Enting,Martin J B Taphoorn,Franchette W P J van den Berkmortel,Rob L. H. Jansen,Dieta Brandsma,Jacoline E C Bromberg,Irene van Heuvel,René M. Vernhout,Bronno van der Holt,Martin J. van den Bent +20 more
TL;DR: The first randomised controlled phase 2 trial of bevacizumab in recurrent glioblastoma reported overall survival at 9 months, and the combined treatment was well tolerated.
Journal ArticleDOI
Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
Walter Taal,Dieta Brandsma,Hein G. de Bruin,Jacoline E C Bromberg,Annemarie T. Swaak-Kragten,Peter A. E. Sillevis Smitt,Corine A. van Es,Martin J. van den Bent +7 more
TL;DR: The occurrence of early pseudo‐progression was retrospectively assessed in a cohort of malignant glioma patients treated with RT/TMZ.
Journal ArticleDOI
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Brigitta G. Baumert,Brigitta G. Baumert,Monika E. Hegi,Martin J. van den Bent,Andreas von Deimling,Thierry Gorlia,Khê Hoang-Xuan,Alba A. Brandes,Guy Kantor,Martin J.B. Taphoorn,Mohamed Ben Hassel,Christian Hartmann,Christian Hartmann,Gail Ryan,David Capper,Johan M. Kros,Sebastian Kurscheid,Sebastian Kurscheid,Wolfgang Wick,Roelien H. Enting,Michele Reni,Brian Thiessen,Frédéric Dhermain,Jacoline E C Bromberg,Loïc Feuvret,Jaap C. Reijneveld,Olivier Chinot,J.M.M. Gijtenbeek,John P. Rossiter,Nicolas Dif,Carmen Balana,Jose Bravo-Marques,Paul Clement,Christine Marosi,Tzahala Tzuk-Shina,Robert A Nordal,Jeremy Rees,Denis Lacombe,Warren P. Mason,Roger Stupp,Roger Stupp +40 more
TL;DR: There was no significant difference in outcome of the overall patient population treated with either radiotherapy alone or TMZ chemotherapy alone, and further data maturation is needed for overall survival analyses and evaluation of the full predictive impact of the molecular subtypes for individualized treatment choices.
Journal ArticleDOI
Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology
Khê Hoang-Xuan,E M Bessell,Jacoline E C Bromberg,Andreas F. Hottinger,Matthias Preusser,Roberta Rudà,Uwe Schlegel,Tali Siegal,Carole Soussain,Carole Soussain,Ufuk Abacioglu,Nathalie Cassoux,Martina Deckert,Clemens M F Dirven,Andrés J.M. Ferreri,Francesc Graus,Roger Henriksson,Ulrich Herrlinger,Martin J.B. Taphoorn,Riccardo Soffietti,Michael Weller +20 more
TL;DR: These guidelines provide consensus considerations and recommendations for diagnosis, assessment, staging, and treatment of primary CNS lymphoma and should aid clinicians in their daily practice and decision making, and serve as a basis for future investigations in neuro-oncology.